The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
暂无分享,去创建一个
[1] Shenmin Zhang,et al. Metabolic-associated fatty liver disease and the risk of cardiovascular disease. , 2022, Clinics and research in hepatology and gastroenterology.
[2] E. Sciatti,et al. Coeliac and cardiovascular disease: a possible relationship between two apparently separate conditions. , 2022, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[3] Jingjing Cai,et al. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. , 2022, Atherosclerosis.
[4] Jingjing Cai,et al. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. , 2022, American journal of physiology. Cell physiology.
[5] K. Hajifathalian,et al. NAFLD or MAFLD: the data behind the debate. , 2022, Hepatobiliary surgery and nutrition.
[6] T. Kanai,et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis , 2022, PloS one.
[7] J. I. Lee,et al. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups , 2022, Digestive Diseases and Sciences.
[8] L. Henry,et al. Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease? , 2022 .
[9] H. Tilg,et al. Global multi-stakeholder endorsement of the MAFLD definition. , 2022, The lancet. Gastroenterology & hepatology.
[10] Hongliang Li,et al. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease , 2022, Frontiers in Endocrinology.
[11] K. Cusi,et al. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.
[12] R. D. de Knegt,et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[13] Y. Fouad,et al. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. , 2021, Journal of hepatology.
[14] A. Sanyal,et al. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] W. Ling,et al. Association of serum methionine metabolites with non-alcoholic fatty liver disease: a cross-sectional study , 2021, Nutrition & Metabolism.
[16] P. Libby,et al. Immune And Inflammatory Mechanisms Mediate Cardiovascular Diseases From Head To Toe. , 2021, Cardiovascular research.
[17] Hongliang Li,et al. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies , 2021, Frontiers in Medicine.
[18] M. Shapiro,et al. Apolipoproteins in vascular biology and atherosclerotic disease , 2021, Nature Reviews Cardiology.
[19] Sang-Man Jin,et al. The association of hepatic steatosis and fibrosis with heart failure and mortality , 2021, Cardiovascular Diabetology.
[20] R. Marfella,et al. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. , 2021, Reviews in cardiovascular medicine.
[21] Y. Bao,et al. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China , 2021, The Journal of clinical endocrinology and metabolism.
[22] M. Orešič,et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests , 2021, Nature Reviews Gastroenterology & Hepatology.
[23] S. Ahn,et al. Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B , 2021, Digestive Diseases and Sciences.
[24] T. Kawaguchi,et al. MAFLD: Renovation of clinical practice and disease awareness of fatty liver , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.
[25] Donghee Kim,et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. , 2021, Journal of hepatology.
[26] Hongliang Li,et al. Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications , 2021, Hepatology.
[27] Hongyan Yang,et al. Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study , 2021, Journal of clinical and translational hepatology.
[28] L. Ji,et al. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?—Results From NHANES III , 2021, Frontiers in Medicine.
[29] Jiaofeng Huang,et al. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis , 2021, Diabetes, metabolic syndrome and obesity : targets and therapy.
[30] M. Kurosaki,et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease , 2021, Journal of gastroenterology and hepatology.
[31] T. Kawaguchi,et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.
[32] Ningjian Wang,et al. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016 , 2021, Chinese medical journal.
[33] M. Nguyen,et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] Ming Yan,et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. , 2021, Journal of hepatology.
[35] C. Mantzoros,et al. Non-Alcoholic Fatty Liver Disease, Insulin Resistance, Metabolic Syndrome and their Association with Vascular Risk. , 2021, Metabolism: clinical and experimental.
[36] Yuri Cho,et al. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? , 2021, Clinical and molecular hepatology.
[37] A. Gomaa,et al. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. , 2021, Journal of hepatology.
[38] C. Byrne,et al. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review , 2021, Diabetes, Obesity & Metabolism.
[39] A. Dhawan,et al. NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.
[40] Pei-Jer Chen,et al. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease , 2021, Gut and liver.
[41] Yong‐ho Lee,et al. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[42] J. Weng,et al. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy , 2020, Chinese medical journal.
[43] M. Silva,et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. , 2020, The lancet. Gastroenterology & hepatology.
[44] I. Bentov,et al. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[45] M. Petroni,et al. Non-alcoholic Fatty Liver Disease: Not Time for an Obituary Just Yet! , 2020, Journal of hepatology.
[46] J. Dufour,et al. Redefining fatty liver disease: an international patient perspective. , 2020, The lancet. Gastroenterology & hepatology.
[47] V. Wong,et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.
[48] B. Staels,et al. Dysregulated lipid metabolism links NAFLD to cardiovascular disease , 2020, Molecular metabolism.
[49] T. Kawaguchi,et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[50] A. Kasturiratne,et al. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study , 2020, medRxiv.
[51] V. Saini,et al. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis , 2020, Oxidative medicine and cellular longevity.
[52] P. Bedossa,et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. , 2020, The lancet. Gastroenterology & hepatology.
[53] G. Targher. Concordance between MAFLD and NAFLD diagnostic criteria in ‘real‐world’ data , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[54] T. Goeser,et al. NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.
[55] Hongliang Li,et al. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. , 2020, Clinical science.
[56] Z. Goodman,et al. From NAFLD to MAFLD: Implications of a Premature Change in Terminology , 2020, Hepatology.
[57] Jiaofeng Huang,et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[58] H. Tilg,et al. From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.
[59] N. Worm. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD , 2020, Nutrients.
[60] H. Tilg,et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.
[61] B. Hanratty,et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.
[62] M. Adeva-Andany,et al. Insulin resistance underlies the elevated cardiovascular risk associated with kidney disease and glomerular hyperfiltration. , 2020, Reviews in cardiovascular medicine.
[63] Hongliang Li,et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. , 2020, Free radical biology & medicine.
[64] Hongliang Li,et al. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases , 2020, Circulation research.
[65] R. Loomba,et al. Advances in non-invasive assessment of hepatic fibrosis , 2020, Gut.
[66] J. Schattenberg,et al. Metabolic inflammation - a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)? , 2020, Gastroenterology.
[67] A. Sanyal,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.
[68] Hongliang Li,et al. Epidemiological Features of NAFLD From 1999 to 2018 in China , 2020, Hepatology.
[69] Manfred von der Ohe,et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.
[70] Hongliang Li,et al. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.
[71] Z. Younossi,et al. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.
[72] Wenyan Jiang,et al. New insights into the immunomodulatory role of exosomes in cardiovascular disease. , 2019, Reviews in cardiovascular medicine.
[73] L. Hodson,et al. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state , 2019, Nature Reviews Endocrinology.
[74] A. Sanyal,et al. Toward More Accurate Nomenclature for Fatty Liver Diseases , 2019, Gastroenterology.
[75] B. Liu,et al. Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis , 2019, Hepatology International.
[76] G. Sumara,et al. The kinase PKD3 provides negative feedback on cholesterol and triglyceride synthesis by suppressing insulin signaling , 2019, Science Signaling.
[77] E. Benjamin,et al. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[78] K. Cusi,et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.
[79] Lan Bai,et al. Innate immune regulatory networks in hepatic lipid metabolism , 2019, Journal of Molecular Medicine.
[80] N. Chalasani,et al. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[81] C. Mantzoros,et al. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.
[82] R. DeFronzo,et al. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. , 2019, Current vascular pharmacology.
[83] Hongliang Li,et al. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. , 2019, Annual review of pathology.
[84] Hongliang Li,et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.
[85] C. Brennan,et al. Inflammatory production of reactive oxygen species by Drosophila hemocytes activates cellular immune defenses. , 2018, Biochemical and biophysical research communications.
[86] A. Voors,et al. Treating oxidative stress in heart failure: past, present and future , 2018, European journal of heart failure.
[87] B. Neuschwander‐Tetri,et al. Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.
[88] M. Packer. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. , 2018, Journal of the American College of Cardiology.
[89] M. Eslam,et al. Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.
[90] G. Shulman,et al. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.
[91] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[92] V. Wong,et al. Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment , 2018, Journal of gastroenterology and hepatology.
[93] David R. Williams,et al. The association between alcohol abuse and neuroendocrine system dysregulation: Race differences in a National sample , 2017, Brain, Behavior, and Immunity.
[94] J. Mi,et al. Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. , 2017, Journal of the American College of Cardiology.
[95] C. Geisler,et al. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. , 2017, The Journal of endocrinology.
[96] Herbert Tilg,et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.
[97] C. Mantzoros,et al. Non-alcoholic fatty liver disease and dyslipidemia: An update. , 2016, Metabolism: clinical and experimental.
[98] S. Francque,et al. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. , 2016, Journal of hepatology.
[99] A. Goldfine,et al. Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations , 2016, Circulation.
[100] Philippe Lehert,et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. , 2016, Gastroenterology.
[101] K. Koh,et al. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. , 2015, International journal of cardiology.
[102] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.
[103] A. Mouton,et al. Alcohol effects on cardiac function. , 2015, Comprehensive Physiology.
[104] F. Violi,et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease , 2014, BMC Gastroenterology.
[105] M. Bennett,et al. Mitochondrial DNA Damage Can Promote Atherosclerosis Independently of Reactive Oxygen Species Through Effects on Smooth Muscle Cells and Monocytes and Correlates With Higher-Risk Plaques in Humans , 2013, Circulation.
[106] William H. Thiel,et al. Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. , 2013, Cardiovascular therapeutics.
[107] P. Cahill,et al. Alcohol and Cardiovascular Disease—Modulation of Vascular Cell Function , 2012, Nutrients.
[108] A. Lonardo,et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. , 2012, Atherosclerosis.
[109] S. Kalhan,et al. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. , 2011, Metabolism: clinical and experimental.
[110] Carla Giordano,et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1 , 2010, Hepatology.
[111] N. Sattar,et al. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data , 2010, Hepatology.
[112] Chris Day,et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.
[113] A. Gasbarrini,et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[114] P. Chou,et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. , 2007, American journal of epidemiology.
[115] G. Lau,et al. Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary , 2007, Journal of gastroenterology and hepatology.
[116] T. Rabelink,et al. Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.
[117] D. Tsikas,et al. Urinary 8-iso-Prostaglandin F2&agr; as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study , 2004 .
[118] R. Busse,et al. Endothelial dysfunction in atherosclerosis. , 1996, Journal of vascular research.
[119] A. Lonardo,et al. Nonalcoholic steatohepatitis and the "bright liver syndrome": should a recently expanded clinical entity be further expanded? , 1995, The American journal of gastroenterology.
[120] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.
[121] A. Craxì,et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. , 2016, Gastroenterology.
[122] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[123] F. Negro,et al. The interaction of metabolic factors with HCV infection: does it matter? , 2012, Journal of hepatology.
[124] K. Dellsperger,et al. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update , 2011, Basic Research in Cardiology.
[125] B. Giusti,et al. Hepatitis C virus RNA localization in human carotid plaques. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[126] L. Schmidt,et al. Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease , 2010 .
[127] S. Baek,et al. Insulin Resistance in Chronic Hepatitis C: Association with Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis , 2008 .
[128] Brian P. Mulhall,et al. Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.
[129] American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[130] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[131] J. Ludwig,et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.
[132] M. Dianzani. [ON THE PATHOGENESIS OF THE ACCUMULATION OF FAT IN HEPATIC STEATOSIS]. , 1964, Rassegna medica sarda.
[133] L. Steinhauer,et al. Annual Review of Medicine. , 1958 .